Jubilant wins Endo discovery deal extension
The year-old collaboration, part of a three year partnership focused on cancer drug candidates, sees the Indian group identify preclinical candidates fro Endo’s ongoing development programme.
While details of the “early success” have not been released it is likely that Jubilant, part of contract research and manufacturing services (CRAMS) giant Jubilant Organosys, has found Endo an interesting candidate.
Sri Mosur, CEO of Bangalore-based Jubilant BioSys, said: “This expansion is a testimony to Jubilant's focus in building world class oncology capabilities, among other therapeutic areas.
“This collaboration further reinforces the concept of globally leveraged R&D that creates a platform for scientists from Endo and Jubilant to collaborate in finding affordable remedies for cancer patients worldwide."
Endo VP of R&D Ivan Gergel was equally positive, explaining that: “We have been impressed by the quality of the science and the progress made to date by the Jubilant team on our ongoing oncology discovery program.
Dr Gergel added that: "Expanding our relationship in this important therapeutic area is consistent with our strategy of building Endo's pipeline using a virtual discovery approach, in conjunction with our in-licensing efforts."
January has been a busy month for Jubilant’s drug discovery operations. Two weeks the Indian firm entered into a co-marketing agreement with DiscoveRx.
That deal was designed to help Jubilant cut the cost of drug development using DiscoveRx’ PathHunter and cAMPHunter cell lines and proprietary enzyme fragment complementation (EFC) chemiluminescent detection technology.